Evidence map›Paper›PMID 36415468›Full record

ArticlemedRxiv : the preprint server for health sciences2023

A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection.

Prashant Dogra, Carmine Schiavone, Zhihui Wang, Javier Ruiz-Ramírez, Sergio Caserta, Daniela I Staquicini, Christopher Markosian, Jin Wang, H Dirk Sostman, Renata Pasqualini and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Prashant DograMathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, TX, USA.
Carmine SchiavoneDepartment of Chemical, Materials and Industrial Production Engineering, University of Naples Federico II, Naples, Italy.
Zhihui WangMathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, TX, USA.
Javier Ruiz-RamírezCentro de Ciencias de la Salud, Universidad Autónoma de Aguascalientes, Aguascalientes, Mexico.
Sergio CasertaDepartment of Chemical, Materials and Industrial Production Engineering, University of Naples Federico II, Naples, Italy.
Daniela I StaquiciniRutgers Cancer Institute of New Jersey, Newark, NJ, USA.
Christopher MarkosianRutgers Cancer Institute of New Jersey, Newark, NJ, USA.
Jin WangImmunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute, Houston, TX, USA.
H Dirk SostmanWeill Cornell Medicine, New York, NY, USA.
Renata PasqualiniRutgers Cancer Institute of New Jersey, Newark, NJ, USA.
Wadih ArapRutgers Cancer Institute of New Jersey, Newark, NJ, USA.
Vittorio CristiniMathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, TX, USA.
Houston Methodist · USRutgers, The State University of New Jersey · USAutonomous University of Aguascalientes · MXCeinge Biotecnologie Avanzate (Italy) · ITUniversity of Naples Federico II · IT

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate CancerR01CA226537 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI ARAP, WADIH, BRINKER, C JEFFREY · 2018 to 2022
$3.2M
miR-155 targeted therapeutics for precision medicine in lung cancerR01CA222007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., CRISTINI, VITTORIO · 2018 to 2022
$2.6M
MOLECULAR REGULATION OF IMMUNITY TO VIRAL INFECTIONSR01AI116644 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, JIN · 2016 to 2020
$2.0M
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancerR01CA253865 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI OZPOLAT, BULENT, WANG, ZHIHUI · 2021 to 2025
$2.0M
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA222007NCI NIH HHS R01 CA226537NCI NIH HHS R01 CA253865NIAID NIH HHS R01 AI116644
6 · The paper itself

Abstract

While the development of different vaccines has slowed the dissemination of SARS-CoV-2, the occurrence of breakthrough infections continues to fuel the pandemic. As a strategy to secure at least partial protection, with a single dose of a given COVID-19 vaccine to maximum possible fraction of the population,

Identifiers

PMID36415468
PMCPMC9681049
OpenAlexW4296157745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.